Hollywood Private Hospital

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Bladder cancer2 trials
• Diffuse large B-cell lymphoma2 trials
• Melanoma2 trials
• Acute myeloid leukaemia1 trial
• Chronic lymphocytic leukaemia1 trial
• Coronary artery disease1 trial
• Follicular lymphoma1 trial
• Myelodysplastic syndromes1 trial
• Myeloproliferative neoplasms1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 38 trials
• Phase 12 trials
• Phase 22 trials
• Phase 1/21 trial

Status

• Active, not recruiting8 trials
• Recruiting3 trials
• Terminated2 trials

Lead sponsor

• Janssen Research & Development, LLC2 trials
• Allogene Therapeutics1 trial
• Amgen1 trial
• Apollo Therapeutics Ltd1 trial
• Aura Biosciences1 trial
• and 7 more

Running trials

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

  NCT07612280· Phase 1/2· Jubilant Therapeutics Inc.· Source

  Contact: Andrew McQuillan

• Recruiting

  Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  NCT06500273· Phase 2· Allogene Therapeutics· Source

  Contact: Chan Cheah, MD (principal investigator)

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

  NCT06073821· Phase 3· BeOne Medicines· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

  NCT05483868· Phase 1· Aura Biosciences· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Active, not recruiting

  Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

  NCT04404283· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

  NCT04224493· Phase 3· Epizyme, Inc.· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Myeloproliferative neoplasms1 recruiting

Closed trials

• Recruiting

  A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

  NCT06372717· Phase 1· Apollo Therapeutics Ltd· Source

  Contact: Apollo Therapeutics

• Terminated

  Olinvacimab With Pembrolizumab in Patients With mTNBC

  NCT04986852· Phase 2· PharmAbcine· Source